Business Context and Reporting Period
Company: Akebia Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 15, 2024
Reporting Period: Event date of April 15, 2024
The filing discloses the entry into a material definitive agreement regarding the supply of vadadustat drug substance.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on a contractual amendment.
Material Changes
The Company entered into Amendment #2 to its existing Supply Agreement with STA Pharmaceutical Hong Kong Limited. Key changes include:
- Term Extension: The agreement term is extended by five years, with a new expiration date of April 2, 2029.
- Pricing Structure: The volume-based pricing structure under the agreement has been amended.
Guidance, Outlook, and Risks
Management Commentary: The filing states that the description of the Amendment is not complete and is qualified by reference to the full text of the Amendment.
Unusual Items/Contingencies: The full text of the Amendment is expected to be filed as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ending June 30, 2024.
Investor Verification Checklist
- Verify the specific details of the amended volume-based pricing structure in the upcoming Form 10-Q.
- Confirm the total financial impact of the five-year extension on future cash flow projections.
- Review the full text of Amendment #2 once filed as an exhibit to the June 30, 2024, 10-Q.